The Pan-Solid Tumor 95- Gene Panel Assay is a small panel product for solid tumors independently developed by MEDx Translational Medicine. It covers relevant genes with clear drug significance recommended by authoritative guidelines. Probe-Based Hybr

HEMECDx, a high-throughput gene assay developed by MEDx Translational Medicine (Suzhou) Co., Ltd, is used to detect abnormal mutations of key genes in hematological malignancies like leukemia and lymphoma. MEDx provides physicians and patients with s

B cell receptor (BCR) sequencing panel is used to detect the rearrangement of human B lymphocyte receptor gene in relative quantitation. The results of this assay mainly assist the diagnosis of ALL, MM and CLL by detecting BCR gene rearrangement, so

This assay has been developed with selected 601 tumor-related genes that cover all the genes of both FDA-approved FoundationOne panel and MSK-IMPACT panel. It can detect the mutation and fusion of the genes to predict the response to a targeted thera

OncoCDx Panel is a pan-solid tumor panel product independently developed by MEDx Translational Medicine. This assay uses Probe-Based Hybridization Capture and Next Generation Sequencing (NGS) technology for the detection of gene mutations, such as po

HRDetectCDx Panel is an HRD score detection Panel independently developed by MEDx Translational Medicine. It is based on 41,000+ high-quality single nucleotide polymorphism sites (SNPs) screened by ChinaMap database of 10,000 individuals. By analyzin

Fibroblast Growth Factor Receptor (FGFR) pathway plays an important role in the occurrence and development of many tumors. The panFGFx was independently developed by MEDx Translational Medicine to detect genes of FGFRs, the upstream FGFs ligand genes

HEMECDx is a high-throughput gene detection product for leukemia and lymphoma patients independently developed by MEDx Translational Medicine (Suzhou) Co., Ltd. (MEDx). MEDx provides physicians and patients with a number of products used to conduct a